编者按：一年一度的临床肿瘤学界奥林匹克盛会——美国临床肿瘤学会（ASCO）年会将于当地时间6月2～6日在芝加哥举行。日前，ASCO会议官网公布了此次年会的日程和摘要题目。头颈部肿瘤领域多项重磅研究即将公布，其中，中山大学肿瘤防治中心共有4项鼻咽癌研究入选口头摘要专场（Oral Abstract Session）和壁报交流专场（Poster Discussion Session），可喜可贺！本文带您提前速览摘要题目。

口头摘要专场（Oral Abstract Session）

Abstract: 6000

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.

N2-3鼻咽癌同步放化疗后辅助顺铂 + 吉西他滨 vs. 顺铂 + 5-氟尿嘧啶化疗：一项多中心、开放标签、随机、对照、Ⅲ期试验

Presenter: 唐林泉教授 | 中山大学肿瘤防治中心

GMT+8 21:00

Abstract: 6001

Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.

局部晚期鼻咽癌的诱导化疗联合放疗 vs. 基于顺铂的同步放化疗：一项开放标签、非劣效性、随机Ⅲ期试验

Presenter: 陈明远教授 | 中山大学肿瘤防治中心

GMT+8 21:12

Abstract: LBA6002

PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM).

PD-1抑制剂信迪利单抗联合诱导化疗和同步放化疗（IC-CCRT）vs. IC-CCRT治疗局部晚期鼻咽癌（LANPC）：多中心、Ⅲ期、随机对照CONTINUUM试验

Presenter: 马骏教授 | 中山大学肿瘤防治中心

GMT+8 21:24

Abstract: 6003

Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.

评估度伐利尤单抗联合紫杉醇卡铂周方案一线治疗不符合基于顺铂治疗条件的复发/转移性头颈部鳞状细胞癌（R/M SCCHN）患者的疗效和安全性：多中心Ⅱ期FRAIL-IMMUNE试验的结果